Synergy CRO

New Year is coming! We have a pleasure to invite clinical trial professionals to the CLINICAL EVE which will take place on December 24. Guests gathering at 18:00, the event will start at 19:00. Agenda: - formal talks (as we are clinical trial professionals); - magical holiday atmosphere with tangerines and other treats 🙂 ; - informal talks about our achievements over the year and plans for the future. The meeting will be held at the anti-cafe "Kotiki Smena". "Kotiki Smena" is the largest cat cafe in Moscow. Address: Moscow, Tovarishchesky Pereulok, 4, bld. 5. Registration fees from the event will be sent to the charity fund "Khoroshee Delo", which is engaged in the rescue and placement of homeless animals, with which the cat cafe cooperates. Tickets are available under the link https://lnkd.in/e_Kg8cZ4 The event is sponsored by DM365 and Synergy Research Group. #clinicaltrials #clinicalresearch #SynergyCRO

Monday good news! We are delighted to share that open-label, randomized, crossover, fully replicated, four-period, two-sequence study of comparative pharmacokinetics and bioequivalence of Dabigatran etexilate has been awarded to Synergy to be conducted in Russia. Study is scheduled to be launched in the first quarter of 2025. 64 healthy volunteers are planned to be enrolled into the study. The IMP is an anticoagulant used for: - preventing the formation of blood clots in the veins in adults who have had an operation to replace a hip or knee; - preventing stroke and systemic embolism in adults who have an abnormal heartbeat called ‘non-valvular atrial fibrillation’ and are considered to be at risk of stroke; - treating deep vein thrombosis pulmonary in adults, and preventing these conditions from occurring again; - treating blood clots in veins and preventing them from occurring again in children. As of date Synergy has conducted more than 50 bioequivalence studies of different complexity. We are the real experts in this field. Feel free to contact us at contact@srgcro.com to discuss your planned BE study. #clinicaltrial #clinicalresearch #bioequivalence #SynergyCRO

Can reprogramming of tumor cells into immune cells fight the cancer? https://lnkd.in/dYCCu8r6 #clinicaltrial #clinicalresearch #cancercare #kidneycancer

We are happy to share that MOH of the Russian Federation approved the conduct of phase III multicenter, randomized parallel-group clinical study to evaluate the efficacy and safety of the combination drug in the treatment of productive cough in children aged 6 to 17 years with acute bronchitis. Approximately 258 pediatric subjects are planned to be screened at several investigational sites. The primary efficacy objective of the study is to assess the proportion of subjects with very high efficacy and high efficacy after the investigational drug treatment. Acute bronchitis is an infectious and inflammatory disease with cough being the main symptom of the disease. Acute bronchitis in children is caused in 90% of cases by respiratory viruses, primarily parainfluenza, influenza, respiratory syncytial virus, rhinovirus, adenovirus, metapneumovirus. Up to 10% of cases of acute bronchitis in childhood, especially in schoolchildren and adolescents, are caused by bacterial pathogens such as Mycoplasma pneumoniae, Chlamydophila pneumoniae and Bordetella pertussis. In pharmacotherapy of acute bronchitis, as a rule, two directions are distinguished: symptomatic treatment and, in case of a protracted course and in the presence of signs of bacterial infection, antibacterial therapy. Best of luck to the study Let’s do it! #clinicaltrial #clinicalresearch #SynergyCRO #Russia #Kazakhstan #pediatrics #acutebronchitis

Need a venting tool? Apply to AI chatbot! https://lnkd.in/eeknmqDm #clinicalresearch #mentalhealth #AI #chatbot

Chew wisely! https://lnkd.in/eWMix7Ax #clinicaltrial #clinicalresearch #dentalhealth

Good Monday news! Central Committee on Bioethics of the Ministry of Health of the Republic of Kazakhstan approved the conduct of the multicenter post marketing observational study in subjects suffering from intrahepatic cholestasis due to chronic liver disease and concomitant metabolic syndrome. The strategic objective of this study is to evaluate the efficacy of ademetionine (in the treatment of patients with chronic liver disease with intrahepatic cholestasis and concomitant metabolic syndrome, who, in the investigator's opinion, may benefit from long-term (>2 months) treatment, to determine the effect of treatment duration on disease dynamics (laboratory parameters, clinical symptoms), including liver and metabolic parameters, lipid profile, metabolism. Overall, these new data are expected to provide important information for developing a treatment strategy for such patients, support the development of clinical guidelines and treatment algorithms for healthcare professionals, which may lead to significant health benefits for comorbid patients with chronic liver disease and metabolic syndrome. The planned number of study subjects is 438 patients. Best of luck to the study team! #clinicaltrials #clinicalresearch #Kazakhstan #Russia #Hepatology #intrahepaticcholestasis

New issue of Orange paper is out! Get the latest data for clinical trials in Russia in the third quarter 2024 here: https://lnkd.in/eX__2Sdx During Q3 2024 the Ministry of Health of the Russian Federation approved the start of 177 new clinical trials of all types, including local and bioequivalence studies. This represents a 14% year on year decline by the total number of studies. The dominant type of clinical trials conducted across Russian sites in Q3 2024 were BE (Bio-equivalent Clinical Trials). The market share of BE studies slightly decreased compared to Q3 2023 – 78% vs. 80%, while the market share of MMCTs (Multinational Multi-center Clinical Trials) remained at the same level vs. Q3 2023 (3% vs. 2%), as well as the share of Local Clinical Trials (LCTs) (19% vs. 18%). Synergy Research Group is a contract research organization successfully operating in Russia and Kazakhstan since 2002. #clinicaltrials #clinicalresearch #SynergyCRO #Russia #Kazakhstan

Just add five extra minutes of exercise per day and see the results 😎 https://lnkd.in/eEWmTWZK #clinicalresearch #bloodpressure #physicalactivity,

Good Tuesday news! Ministry of health of Russian Federation approved the conduct of an open-label, phase I, single-center study of an enterovirus-based drug in patients with histologically confirmed solid tumors. Oncological diseases remain one of the leading causes of death worldwide, despite the obvious progress in the development of treatment methods, both surgical and conservative. It is known that tumor cells use various mechanisms that allow them to successfully resist the action of chemo- and targeted drugs, and most importantly, suppress the immune system of the body carrying the tumor. In recent decades, oncolytic antitumor virotherapy has been actively developing, the therapeutic effect of which is due to various mechanisms that affect various components of the malignant process. In Russia, there are currently no drugs based on oncolytic viruses for the treatment of patients with malignant tumors, which determines the relevance of the development and registration of domestic original drugs. The primary purpose of the study is to evaluate the safety and tolerability of different doses and administration regimens of the investigational drug in patients with a histologically confirmed diagnosis of solid tumor. The secondary objectives include description of the pharmacokinetic parameters of the investigational drug and evaluation of its therapeutic effect. Clinical trials are an essential step in providing access to urgently needed lifesaving therapies and lead to better outcomes for current and future patients. #clinicaltrial #clinicalresearch #onclology #solidtumors #SynergyCRO #Russia #Kazakhstan